 "AIIMS Delhi to start screening children for Covaxin trials: Sources")
The screening of children aged 6 to 12 years for the clinical trials of indigenously developed Covid-19 vaccine, Bharat Biotech's Covaxin is scheduled to start from Tuesday.
According to sources, the recruitment for clinical trials of Covaxin among those aged 12 to 18 years is over. They have been given a single dose of vaccine.
After the recruitment of 6-12 yr old children AIIMS Delhi will be conducting trials for the age group 2-6 yr old. The trails are taking place at 525 centres.
AIIMS Patna, Mysore Medical College and Reaserch Institute in Karnataka have also been selected to conduct clinical trials on children.
"We have started recruitment for children aged 6-12 years. Recruitments for clinical trails on children aged 12-18 years is over. They will be kept under observation." said Prabhat Kumar Singh, Director, AIIMS, Patna.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app